Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Receptor de antígeno quimérico mejorado de células T para el tratamiento del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20150903002
Publicado:
14/09/2015
Caducidad:
13/09/2016
Resumen:
Científicos de un centro médico de una universidad alemana han desarrollado un receptor de antígeno quimérico biespecífico (CAR) que mejora el rendimiento de células T genéticamente modificadas que expresan estos polipéptidos CAR en su superficie. Esta plataforma de CAR se utiliza en el tratamiento del cáncer y es útil en la terapia de infecciones víricas (hepatitis B y citomegalovirus). La universidad ofrece la licencia de patente y colaboración en materia de investigación con opción de licencia a la industria farmacéutica.

Details

Tittle:
Improved chimeric antigen receptor T-cells for cancer treatment.
Summary:
Scientists from a German university medical centre have developed a bispecific chimeric antigen receptor (CAR), which improves the performance of genetically engineered T-cells expressing these CAR polypeptides on their surface. With this described CAR platform technology any tumor could be addressed. The university offers a patent license as well as a research collaboration with licensing option to the pharmaceutical industry across Europe and beyond.
Description:
A German university medical centre in the field of life sciences offers new chiemeric antigen receptor (CAR) T-cells.

Adoptive T-cell therapy is a very promising approach in the treatment of cancer. Early phase clinical trials with genetically engineered T-cells expressing a tumor-specific CAR show significant efficacy in the treatment. However, currently used CAR modified T-cells for antigen-directed targeting towards tumor cells have insufficient performance in the anti-tumor attack, e. g. less amplification and cytolytic activity after the transfer of the modified T-cells into the patient.

The developed bispecific CAR improves the performance of genetically engineered T-cells expressing these CAR polypeptides on their surface. The bispecific CAR comprises two antibody units, with one antibody unit being an anti-CD30 single chain antibody unit and the other antibody unit being an antibody unit specific for an antigen present on the surface of a predetermined target cell, e. g. for the tumor carcino-embryonic antigen (CEA) on breast cancer cells. Hence this construct allows specific targeting of any given tumor type, e. g. colon or breast cancer (specificity according to the non-CD30-part). The anti-CD30 part will enable an efficient tumor attack with the modified T-cells working as helper in therapy.

With the described CAR platform technology each tumor could be addressed. In addition the technology could be useful for the therapy of viral infections (e. g. hepatitis virus B, cytomegalovirus).

The University Medical Center offers a patent license as well as a research collaboration with licensing option. Partners should come from pharmaceutical industry with R-Y-D activity in cancer therapy.
Advantages and Innovations:
The advantage is, that the percentage of specifically lysed tumor cells is higher using the bispecific CAR molecule as compared to a monospecific CAR solely containing the antibody binding unit specific for the antigen present on the surface of the tumor cell. Most strikingly, this newly constructed bispecific CAR increases T-cell activity even in the absence of CD30 on the target cell.

The innovative aspects in brief:

- Higher proliferation of CAR T-cells
- Increased cytotoxic activity against target cells
-Platform technology allows addressing any given tumor cell
Stage of Development:
Already on the market
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European patent application and a PCT-application are pending.

Partner sought

Type and Role of Partner Sought:
The university offers a patent license as well as a research collaboration with licensing option to pharmaceutical industry. The partner should be active in cancer therapy and research.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001012 Investigaciones médicas
03004007 Pharmaceutics